A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation

References

• RoscoeJAMorrowGRColagiuriBInsight in the prediction of chemotherapy-induced nauseaSupport Care Cancer201018786987619701781
   PubMed Web of Science ®Google Scholar
• HeskethPJGandaraDRSerotonin antagonists: a new class of antiemetic agentsJ Natl Cancer Inst19918396136201850806
   PubMedGoogle Scholar
• National Comprehensive Cancer Network (NCCN)NCCN Clinical Practice Guidelines in Oncology: Antiemesis v 1.20142014Fort Washington, PANCCN2013 Available from: http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
   Google Scholar
• RoilaFHerrstedtJAaproMESMO/MASCC Guidelines Working GroupGuideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conferenceAnn Oncol201021Suppl 5v232v24320555089
   PubMed Web of Science ®Google Scholar
• BaschEPrestrudAAHeskethPJAmerican Society of Clinical OncologyAntiemetics: American Society of Clinical Oncology clinical practice guideline updateJ Clin Oncol201129314189419821947834
   PubMed Web of Science ®Google Scholar
• KuryshevYABrownAMWangLBenedictCRRampeDInteractions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channelsJ Pharmacol Exp Ther2000295261462011046096
   PubMed Web of Science ®Google Scholar
• Kytril (granisetron hydrochloride) tablets oral solution [prescribing information]Nutley, NJRoche Pharmaceuticals2010
   Google Scholar
• Kytril (granisetron hydrochloride) injection [prescribing information]San Francisco, CAGenentech, Inc.2011
   Google Scholar
• Zofran (ondansetron hydrochloride) injection [prescribing information]Research Triangle Park, NCGlaxoSmithKline2012
   Google Scholar
• Zofran (ondansetron hydrochloride) tablets [prescribing information]Research Triangle Park, NCGlaxoSmithKline2011
   Google Scholar
• Anzemet injection (dolasetron mesylate) [prescribing information]Bridgewater, NJSanofi-Aventis2011
   Google Scholar
• Anzemet tablets (dolasetron mesylate) [prescribing information]Bridgewater, NJSanofi-Aventis2011
   Google Scholar
• US Food and Drug Administration (FDA)FDA drug safety communication: abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate) [web page on the Internet]Silver Spring, MDFDA2010 [updated December 22, 2010]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm237081.htmAccessed February 28, 2014
   Google Scholar
• FDASafety: Kytril (granisetron hydrochloride) injection, tablets and oral solution [web page on the Internet]Silver Spring, MDFDA2009 [updated October 21, 2009]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm187526.htmAccessed February 28, 2014
   Google Scholar
• FDAFDA drug safety communication: abnormal heart rhythms may be associated with use of Zofran (ondansetron) [web page on the Internet]Silver Spring, MDFDA2011 [updated June 29, 2012]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm271913.htmAccessed February 28, 2014
   Google Scholar
• FDAFDA drug safety communication: updated information on 32 mg intravenous ondansetron (Zofran) dose and pre-mixed ondansetron products [web page on the Internet]Silver Spring, MDFDA2012 [updated December 6, 2012]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm330049.htmAccessed February 28, 2014
   Google Scholar
• Aloxi (palonosetron HCl) injection [prescribing information]Woodcliff Lake, NJEisai Pharmaceuticals2008
   Google Scholar
• AaproMBourkeJPRapid intravenous administration of granisetron prior to chemotherapy is not arythmogenic: results of a pilot studyEur J Cancer200339792793112706361
   PubMed Web of Science ®Google Scholar
• CarmichaelJPhilipPAForfarCHarrisALAn open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant diseaseCancer Chemother Pharmacol1995371–21341387497582
   PubMed Web of Science ®Google Scholar
• CarmichaelJHarrisALThe cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapyCancer Chemother Pharmacol200453212312814634790
   PubMed Web of Science ®Google Scholar
• JantunenITKatajaVVMuhonenTTParviainenTEffects of granisetron with doxorubicin or epirubicin on ECG intervalsCancer Chemother Pharmacol19963755025048599877
   PubMed Web of Science ®Google Scholar
• UpwardJWArnoldBDLinkCPierceDMAllenATaskerTCThe clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonistEur J Cancer199026Suppl 1S12S152169778
   PubMed Web of Science ®Google Scholar
• FriedmanCJBurrisHA3rdYocomKBlackburnLMGrubenDOral granisetron for the prevention of acute late onset nausea and vomiting in patients treated with moderately emetogenic chemotherapyOncologist20005213614310794804
   PubMedGoogle Scholar
• MasonJWSelnessDSMoonTEO’MahonyBDonachiePHowellJPharmacokinetics and repolarization effects of intravenous and transdermal granisetronClin Cancer Res201218102913292122452942
   PubMed Web of Science ®Google Scholar
• GrousJRiegelEGabrailNPhase III study of sustained release granisetron (APF530) compared to palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV)J Clin Oncol200927Suppl abstr 9627
   Google Scholar
• US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic DrugsRockville, MDUS Department of Health and Human Services, FDA, CDER, CBER2005 Available from: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129357.pdfAccessed February 28, 2014
   Google Scholar
• International Conference on HarmonizationGuidance for Industry: E6 Good Clinical Practice: Consolidated Guidance2006 Available from: http://www.fda.gov/downloads/Drugs/GuidanceCompliance-RegulatoryInformation/Guidances/UCM073122.pdfAccessed March 17, 2014
   Google Scholar
• World Medical Association (WMA)WMA Declaration of Helsinki Ethical Principles for Medical Research Involving Human SubjectsFerney-VoltaireWMA2008 Available from: http://www.wma.net/en/30publications/10policies/b3/Accessed February 28, 2014
   Google Scholar
• GabrailNYanagiharaRHCooperWPharmacokinetics (PK), tolerability, and efficacy of APF530 in patients receiving moderately (MEC) and highly (HEC) emetogenic chemotherapy: Phase II trial resultsJ Clin Oncol201331Suppl abstr e20518
   Google Scholar